... to August 2014, we usually used neoadjuvant DCF therapy; we then completely transitioned to using neoadjuvant DCS therapy. Results: A total of 144 patients received one of these triplet regimens as neoadjuvant chemotherapy: DCF therapy to 67 patients and DCS therapy to 77 patients. After propensity score...

...Mohan Hingorani; Rebecca Goody; Georgios Bozas; Khwaja Zahid; David James Mitton; Prashant Jain; Vincent Wong; Rajarshi Roy Background: Neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) are accepted standards of care for the management of adenocarcinoma of the esophagus...

...Osamu Shiraishi; Hiroaki Kato; Kota Momose; Yoko Hiraki; Atsushi Yasuda; Masayuki Shinkai; Motohiro Imano; Takushi Yasuda Introduction: This study aimed to clarify the impact of the average relative dose intensity (RDI) of neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF...

... for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the adjuvant setting, but not in the neoadjuvant chemotherapy (NAC) setting. We investigated whether anthracycline can be omitted in HER2-positive early breast cancer patients receiving neoadjuvant taxane plus...

... was to evaluate the response to neoadjuvant chemotherapy (NACT) in LACC by 2D/3D ultrasound examination. Materials and Methods: We prospectively enrolled patients affected by histologically and clinically confirmed LACC. All patients were scheduled for 3 cycles of platinum-based NACT followed by radical surgery...

... transvaginal ultrasound (3D TV-US) for evaluation of parametrial status in locally advanced cervical cancer patients after neoadjuvant chemotherapy (NACT), using histology as the gold standard. Methods: Consecutive patients with histologically confirmed cervical cancer were staged according to FIGO...

... of the top 10 diseases with the highest rate of stage III cancer progression. Objective: This study aims to determine the 5-year survival rate of patients with NPC based on tumor response and their prognostic factors after receiving neoadjuvant chemotherapy, followed by chemoradiation. Methods: The records...

... be considered. We investigated prognostic factors before neoadjuvant chemotherapy (NAC) among HER2-positive invasive breast cancer patients and those after NAC among patients who did not achieve pathological complete response (pCR) using conventional adjuvant trastuzumab. Methods: HER2-positive primary breast...

...Kausar Suleman; Osama Almalik; Emaan Haque; Ali Mushtaq; Ahmed Badran; Adher Alsayed; Dahish Ajarim; Taher Al-Tweigeri; Noha Jastaniyah; Tusneem Elhassan; Wafa Alkhayal Background: There is a paucity of literature examining the impact of timing of surgery after neoadjuvant chemotherapy. Objective...

... 2019, 105 patients who underwent neoadjuvant chemotherapy followed by surgery were included in this study. Of these patients, 40 received intravenous magnesium premedication (magnesium group), whereas the remaining 65 did not (control group). We investigated the -association between magnesium...

...Norihiro Matsuura; Masaaki Motoori; Kazumasa Fujitani; Yujiro Nishizawa; Hisateru Komatsu; Yasuhiro Miyazaki; Susumu Miyazaki; Akira Tomokuni; Takamichi Komori; Kazuhiro Iwase Purpose: Neoadjuvant chemotherapy (NAC) followed by surgery is a promising treatment strategy for patients with advanced...

... an effective neoadjuvant regimen to achieve an improvement in histologic response. Methods: Twenty-nine patients with a high-grade osteosarcoma received 2 courses of neoadjuvant chemotherapy non-randomly with either the MAP regimen (methotrexate 12 g/m 2 , cisplatin 120 mg/m 2 , and doxorubicin 75 mg/m 2...

... constitutes appropriate additional therapy is unknown. Methods: A total of 101 consecutive patients with cStage I B-III esophageal cancer were treated with preoperative DCF between April 2011 and December 2015. After completing 2 cycles of DCF neoadjuvant chemotherapy (NAC), esophagectomy was performed. We...

...) of capecitabine combined with oxaliplatin and irinotecan (XELOXIRI) as a neoadjuvant chemotherapy in patients with locally advanced rectal cancer. Method: Patients received irinotecan and oxaliplatin (85 mg/m 2 ) on day 1, and capecitabine (1,000 mg/m 2 orally twice daily) on days 1–7 of a biweekly schedule...

... for advanced esophageal cancer. Severe toxicities may influence body composition, including skeletal muscle mass, and increase postoperative complications. The purpose of this study was to evaluate the influence of sarcopenia, changes in body composition, and adverse events during neoadjuvant chemotherapy...

... Gastric cancer Neoadjuvant chemotherapy Capecitabine Oxaliplatin Our ancillary study prospectively investigated the potential role of FDG-PET/CT to early predict outcomes in terms of pathological response. In GC, there are only few studies using FDG-PET/CT to predict responses to neoadjuvant...

...Dora Niedersüss-Beke; Thomas Puntus; Thomas Kunit; Birgit Grünberger; Michael Lamche; Wolfgang Loidl; Reinhard Böhm; Nicole Kraischits; Stefan Kudlacek; Paul Schramek; Johannes G. Meran Background: Neoadjuvant chemotherapy with methotrexate-vinblastine-doxorubicin-cisplatin (MVAC) is the standard...

...Keishi Yamashita; Kei Hosoda; Hiromitsu Moriya; Chikatoshi Katada; Mitsuhiro Sugawara; Hiroaki Mieno; Shoko Komori; Natsuya Katada; Masahiko Watanabe Background: Neoadjuvant chemotherapy (NAC) has become prevalent in esophageal squamous cell carcinoma (ESCC), but its long-term prognostic advantages...

...Osamu Shiraishi; Makoto Yamasaki; Tomoki Makino; Masaaki Motoori; Hiroshi Miyata; Masayuki Shinkai; Yutaka Kimura; Motohiro Hirao; Kazumasa Fujitani; Shigeyuki Tamura; Kenji Kobayashi; Masahiko Yano; Yuichiro Doki; Takushi Yasuda Background: Neoadjuvant chemotherapy for resectable advanced...

... ovarian cancer, tubal carcinoma, or primary peritoneal carcinoma of stages III or IV undergoing neoadjuvant chemotherapy (NAC) followed by cytoreductive surgery, according to the number of cycles performed. Methods: This retrospective study was conducted in three main oncology centres in the east...